E-LIB Suche - Ergebnisse für: Zinner, Ralph G.

1

Description of a Lung Cancer Hotspot: Disparities in Lung C..:

Brainson, Christine F. ; Huang, Bin ; Chen, Quan...
Clinical Lung Cancer. 22 (2021) 6 - p. e911-e920 , 2021

Link: https://doi.org/10.1016/..

2

S6K1 blockade overcomes acquired resistance to EGFR-TKIs in..:

Shen, Hua ; Wang, Gao-Chan ; Li, Xiang...
Oncogene. 39 (2020) 49 - p. 7181-7195 , 2020

Link: https://doi.org/10.1038/..

3

Dose‐escalation study of vemurafenib with sorafenib or criz..:

Janku, Filip ; Sakamuri, Divya ; Kato, Shumei...
Cancer. 127 (2020) 3 - p. 391-402 , 2020

Link: https://doi.org/10.1002/..

4

Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsq..:

Patel, Jyoti D. ; Paz-Ares, Luis ; Zinner, Ralph G....
Clinical Lung Cancer. 19 (2018) 6 - p. e823-e830 , 2018

Link: https://doi.org/10.1016/..

5

Phase 1 study of the combination of vemurafenib, carboplati..:

Bhatty, Minny ; Kato, Shumei ; Piha‐Paul, Sarina A....
Cancer. 125 (2018) 3 - p. 463-472 , 2018

Link: https://doi.org/10.1002/..

6

Parametric dose standardization for optimizing two-agent co..:

Thall, Peter F. ; Nguyen, Hoang Q. ; Zinner, Ralph G.
Journal of the Royal Statistical Society. Series C (Applied Statistics). 66 (2017) 1 - p. 201-224 , 2017

Link: https://www.jstor.org/st..

7

Parametric Dose Standardization for Optimizing Two-Agent Co..:

Thall, Peter F. ; Nguyen, Hoang Q. ; Zinner, Ralph G.
Journal of the Royal Statistical Society Series C: Applied Statistics. 66 (2016) 1 - p. 201-224 , 2016

Link: https://doi.org/10.1111/..

8

Phase I dose-escalation study of the mTOR inhibitor sirolim..:

Park, Haeseong ; Garrido-Laguna, Ignacio ; Naing, Aung...
Oncotarget. 7 (2016) 41 - p. 67521-67531 , 2016

Link: https://doi.org/10.18632..

9

Sleep quality and its association with fatigue, symptom bur..:

George, Goldy C. ; Iwuanyanwu, Eucharia C. ; Anderson, Karen O....
Cancer. 122 (2016) 21 - p. 3401-3409 , 2016

Link: https://doi.org/10.1002/..

10

Advanced malignancies treated with a combination of the VEG..:

Liu, Xiaochun ; Kambrick, Susan ; Fu, Siqing...
Oncotarget. 7 (2016) 17 - p. 23227-23238 , 2016

Link: https://doi.org/10.18632..

11

PRONOUNCE: Randomized, Open-Label, Phase III Study of First..:

Zinner, Ralph G. ; Obasaju, Coleman K. ; Spigel, David R....
Journal of Thoracic Oncology. 10 (2015) 1 - p. 134-142 , 2015

Link: https://doi.org/10.1097/..

12

Actionable mutations in plasma cell-free DNA in patients wi..:

Janku, Filip ; Angenendt, Philipp ; Tsimberidou, Apostolia M....
Oncotarget. 6 (2015) 14 - p. 12809-12821 , 2015

Link: https://doi.org/10.18632..

13

BRAF mutation testing with a rapid, fully integrated molecu..:

Janku, Filip ; Claes, Bart ; Huang, Helen J....
Oncotarget. 6 (2015) 29 - p. 26886-26894 , 2015

Link: https://doi.org/10.18632..

14

Erratum: Actionable mutations in plasma cell-free DNA in pa..:

Janku, Filip ; Angenendt, Philipp ; Tsimberidou, Apostolia M....
Oncotarget. 6 (2015) 27 - p. 24581-24581 , 2015

Link: https://doi.org/10.18632..

15

A phase 2 cooperative group adjuvant trial using a biomarke..:

Bepler, Gerold ; Zinner, Ralph G. ; Moon, James...
Cancer. 120 (2014) 15 - p. 2343-2351 , 2014

Link: https://doi.org/10.1002/..